| COMMENTS |
The move did not come as a surprise - For Aventis, it is a crafty way for the firm to trim its unwieldy prodt portfolio & dump excess R&D capacity as its prede cessor firms, Hoechst & Rhône-Poulenc, attempt to merge their operations - DuPont has long needed a stronger pharma. presence in Europe |
| STATUS | The deal is expected to close in mid-2000 |
| UPDATE | 03.00 |
| ALLIANCE |
- Aventis Pharma Deutschland GmbH (1) & - DuPont Pharmaceuticals (2 signed a letter of intent to form a European alliance to discover, develop & market pharmaceuticals in certain therapeutic classes. Under the agreement: - (2) will acquire (1)'s R&D facility in Romainville, France, & assume responsibility for employees at the facility - (2) will acquire R&D projects in the areas of anti-infectives bone disease & hormone replacement & will have access to the Romainville chemical library The facility had belonged to Roussel Uclaf prior to being acquired by Hoechst. (2) also will have exclusive marketing rights in several European countries to 8 prodts, mostly in - Anti-inflammatory area - Asthma area - Cardiovascular area - Hormone replacement area - Pain therapy area The prodts have combined annual sales in Europe of $250 million |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |